Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUAK1 | O60285 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | CSF1R | P07333 | 3/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756769 | 0.94 | NUAK1 (0.54) | NUAK1JAK2SRCCDK2CCNA2 | |
| SCHEMBL13756842 | 0.93 | NUAK1 (0.45) | NUAK1JAK2SYKCDK2CCNA2 | |
| SCHEMBL13756768 | 0.85 | NUAK1 (0.44) | NUAK1JAK2CDK2CCNE1CCNA2 | |
| SCHEMBL13756697 | 0.82 | CSF1R (0.41) | JAK2CDK2CCNA2BRD4CSF1R | |
| SCHEMBL13756846 | 0.81 | CDK2 (0.44) | JAK2SRCSYKCDK2CCNE1 | |
| SCHEMBL4290551 | 0.81 | AURKA (0.52) | JAK2SRCSYKCDK2BRD4 | |
| SCHEMBL13756766 | 0.79 | NTRK1 (0.49) | JAK2CDK2CCNE1CCNA2JAK1 | |
| SCHEMBL13756776 | 0.78 | PDGFRB (0.52) | NUAK1JAK2SRCCDK2CCNE1 | |
| SCHEMBL13756756 | 0.78 | PTGS2 (0.48) | JAK2CDK2CCNE1BRD4EGFR | |
| SCHEMBL13756693 | 0.78 | PTGS2 (0.47) | JAK2CDK2CCNE1BRD4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | NUAK1 488/4885BTK 4/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.